Showing 161-170 of 9661 results for "".
- Sanofi Halts Amlitelimab Development in Atopic Dermatitishttps://practicaldermatology.com/news/sanofi-halts-amlitelimab-development-in-atopic-dermatitis/2487921/Sanofi has announced it will discontinue the clinical development of amlitelimab for moderate-to-severe atopic dermatitis (AD), ending plans to submit the investigational therapy for global regulatory review after determining it would not provide a meaningful adva
- Tapinarof Demonstrates Consistent Efficacy Across Pediatric and Adult Patients With Atopic Dermatitishttps://practicaldermatology.com/news/tapinarof-demonstrates-consistent-efficacy-across-pediatric-and-adult-patients-with-atopic-dermatitis/2487900/Organon will present new data from a post hoc pooled analysis of the Phase 3 ADORING 1 and ADORING 2 trials at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting in Minneapolis, Minnesota, showing that tapinarof (VTAMA) cream 1% produced early and consistent improvements in patients
- Lebrikizumab Meets Primary Endpoints in Phase 3 ADorable-1 Trial for Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/lebrikizumab-meets-primary-endpoints-in-phase-3-adorable-1-trial-for-pediatric-atopic-dermatitis/2487891/Lebrikizumab demonstrated significant improvements in disease severity and symptoms in infants, children, and adolescents with moderate-to-severe atopic dermatitis (AD), according to Week 16 results from the phase 3 ADorable-1 trial presented at the 2026 Society f
- SKNV Secures Exclusive Rights to Patented 5-FU/Calcipotriene Combination for Actinic Keratosishttps://practicaldermatology.com/news/sknv-secures-exclusive-rights-to-patented-5-fucalcipotriene-combination-for-actinic-keratosis/2487883/SKNV has obtained exclusive commercialization rights under a sublicense to a patent covering the combination of fluorouracil (5-FU) and calcipotriene, according to an announcement. The patented combination is currently avai
- Psychological Burden of Atopic Dermatitis Appears Greatest in Children and Adolescentshttps://practicaldermatology.com/news/psychological-burden-of-atopic-dermatitis-appears-greatest-in-children-and-adolescents/2487888/Children and adolescents with atopic dermatitis (AD) may experience a greater psychological burden than adults with the disease, according to a systematic review and meta-analysis published in Frontiers in Public Health.¹ However, investigators cautioned
- Farming-Associated Maternal Microbiome Linked With Lower Early Childhood Atopic Diseasehttps://practicaldermatology.com/news/study-farming-associated-maternal-microbiome-linked-with-lower-early-childhood-atopic-disease/2487882/A maternal gut microbiome shaped by a traditional farming lifestyle may help explain the protective effect of prenatal farm exposure against atopic disease in children, according to new research published in Allergy.
- Study: Anumigilimab Well Tolerated in HS and Palmoplantar Pustulosishttps://practicaldermatology.com/news/study-anumigilimab-well-tolerated-in-hs-and-palmoplantar-pustulosis/2487876/Anumigilimab was generally well tolerated in patients with hidradenitis suppurativa (HS) or palmoplantar pustulosis (PPP), while providing preliminary signals of clinical activity in both neutrophil-driven inflammatory skin diseases, results from a Phase 1b study
- Imaging-Guided Tape Stripping Standardizes Molecular Profiling in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/imaging-guided-tape-stripping-standardizes-molecular-profiling-in-pediatric-atopic-dermatitis/2487887/A minimally invasive, imaging-guided tape-stripping technique may provide a standardized method for molecular profiling and treatment monitoring in pediatric atopic dermatitis (AD), according to findings published online ahead of print in the
- Oral Vitamin D Associated With Faster Recovery From Cancer Therapy Skin Toxicitieshttps://practicaldermatology.com/news/oral-vitamin-d-associated-with-faster-recovery-from-cancer-therapy-skin-toxicities/2487854/High-dose oral vitamin D may offer a promising supportive care option for patients experiencing chemotherapy- and radiation-induced skin toxicities, according to a multicenter case series in JAMA Dermatology.
- American Pharmacists Association Urges FDA to Put Patient Safety First in Peptide Reviewhttps://practicaldermatology.com/news/apha-urges-fda-to-put-patient-safety-first-in-peptide-review/2487836/The American Pharmacists Association (APhA) is urging the US Food and Drug Administration (FDA) to prioritize patient safety, scientific evidence, and regulatory oversight in its decision-making process, according to